Zimbabwe has turned down a significant American health deal worth $367m (272 million pounds) over five years over the United States' demand for confidential biological samples.
The decision became public following a official document dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official spokesman later clarified that the US was requesting biological samples for scientific study and commercial purposes while refused to guarantee the benefits from any future medical innovations.
"We are forced to start the challenging and unfortunate task of winding down our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for more negotiations to reach a deal acceptable to both sides so the country's critical HIV programme can proceed.
Broader Background
This development comes after a comparable case in Kenya, where a court halted a related health funding agreement after legal challenges were raised about the safety of Kenyans' health data.
After returning to office last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had managed aid for the American government, but Trump claimed its spending was "wasteful" and his administration was seeking government-to-government deals to enhance transparency and accountability.
Based on statements, Sixteen African countries have to date signed these new health pacts, constituting over $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership could have provided extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy via US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information for a long time, without any equivalent promise of access to any medical innovations – like new medicines or tests – that might be developed from that shared data," he stated.
"Put simply, our country would provide the raw materials for scientific discovery without any assurance that the resulting innovations would be accessible to our people should a new health crisis emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its pursuit of one-on-one deals were disrupting frameworks already set up through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to manage potential pandemics.
"This framework is designed to guarantee that when a nation provides its samples, the benefits – such as medicines and cures – are shared equitably, not commercialised solely by those with the resources to develop them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to ongoing dialogue with our US partners on how subsequent co-operation could be designed in a way that respects the independence and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but suggested that talks must proceed considering much of the nation's Aids initiatives depended on external financing.
"Where technical issues arise, including those relating to information security or implementation frameworks, these can frequently be addressed via technical clarification and mutually agreed protections," the group commented.
The halted deal highlights the complex debate between accepting much-needed foreign assistance and safeguarding a country's data in an increasingly data-driven world.